Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arcutis Biotherapeutics, Inc. - Common stock (NQ:ARQT)

29.80 +0.22 (+0.74%)
Streaming Delayed Price Updated: 3:31 PM EST, Jan 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 893,796
Open 29.18
Bid (Size) 29.78 (100)
Ask (Size) 29.82 (500)
Prev. Close 29.58
Today's Range 28.86 - 30.09
52wk Range 11.13 - 31.77
Shares Outstanding 50,241,789
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Arcutis Biotherapeutics (NASDAQ:ARQT) Combines High-Growth Momentum with Bullish Technical Setup ↗
Arcutis Biotherapeutics (ARQT) combines strong revenue growth & earnings momentum with a bullish technical chart setup, signaling a potential breakout opportunity. 
Via Chartmill
News headline image
Arcutis Stock Is Up 100% in a Year but Here’s Why One Fund Still Sold 1 Million Shares ↗
Even after cutting back, this remains the fund’s largest bet and the timing lines up with a pivotal stretch for Arcutis’ pipeline. 
Via The Motley Fool

Performance

YTD
+2.8%
+2.8%
1 Month
-4.0%
-4.0%
3 Month
+40.3%
+40.3%
6 Month
+109.6%
+109.6%
1 Year
+89.1%
+89.1%

More News

Read More
News headline image
Fund Discloses Increased Mineralys Bet Amid 200% Stock Run as New Drug Application Nears ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
The Biotech Renaissance: Innovation and M&A Frenzy Spark a Historic Year-End Rally
Via MarketMinute
Topics ETFs Economy Intellectual Property
News headline image
This Biotech Stock Could Cure Your Portfolio's Pain ↗
Via The Motley Fool
News headline image
ARCUTIS BIOTHERAPEUTICS INC (NASDAQ:ARQT) Shows Strong Technical and Fundamental Momentum ↗
Via Chartmill
News headline image
Arcutis Strengthens Board of Directors with New Appointment of Amit Munshi and Honors Retirement of Bhaskar Chaudhuri
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Why Shares in Arcutis Biotherapeutics Surged Again This Week ↗
Via The Motley Fool
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
Via Benzinga
News headline image
FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Peering Into Arcutis Biotherapeutics Inc's Recent Short Interest ↗
Via Benzinga
News headline image
Arcutis Completes Enrollment in INTEGUMENT-INFANT Phase 2 Study Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
ARCUTIS BIOTHERAPEUTICS INC (NASDAQ:ARQT) Combines Strong Trend with High-Growth Momentum ↗
Via Chartmill
News headline image
Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data of ZORYVE® (roflumilast) Foam 0.3% in Individuals with Seborrheic Dermatitis in American Journal of Clinical Dermatology
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Mother-Daughter Duo, Tori Spelling and Stella McDermott, Partner With Arcutis Biotherapeutics in the Free to Be Me Campaign, Urging People With Inflammatory Skin Conditions to Speak With Their Healthcare Provider About Long-Term Treatments
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Arcutis Launches ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Children Ages 2 to 5
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
These stocks are moving in today's session ↗
Via Chartmill
News headline image
Arcutis Q3 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Top stock movements in today's session. ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
Via Benzinga
News headline image
Crude Oil Falls Over 2%; PayPal Shares Spike Higher ↗
Via Benzinga
News headline image
Here's Why This Biotherapeutics Company's Stock Surged Higher by 30% Today ↗
Via The Motley Fool
News headline image
Arcutis Tops A Profit-Taking Zone After Smashing Forecasts. But There Was Another Surprise. ↗
Via Investor's Business Daily
News headline image
Traders are paying attention to the gapping stocks in Tuesday's session. ↗
Via Chartmill
News headline image
Wayfair, Qorvo, Celestica, United Parcel Service, Regeneron Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday ↗
Via Benzinga

Frequently Asked Questions

Is Arcutis Biotherapeutics, Inc. - Common stock publicly traded?
Yes, Arcutis Biotherapeutics, Inc. - Common stock is publicly traded.
What exchange does Arcutis Biotherapeutics, Inc. - Common stock trade on?
Arcutis Biotherapeutics, Inc. - Common stock trades on the Nasdaq Stock Market
What is the ticker symbol for Arcutis Biotherapeutics, Inc. - Common stock?
The ticker symbol for Arcutis Biotherapeutics, Inc. - Common stock is ARQT on the Nasdaq Stock Market
What is the current price of Arcutis Biotherapeutics, Inc. - Common stock?
The current price of Arcutis Biotherapeutics, Inc. - Common stock is 29.80
When was Arcutis Biotherapeutics, Inc. - Common stock last traded?
The last trade of Arcutis Biotherapeutics, Inc. - Common stock was at 01/08/26 03:31 PM ET
What is the market capitalization of Arcutis Biotherapeutics, Inc. - Common stock?
The market capitalization of Arcutis Biotherapeutics, Inc. - Common stock is 1.50B
How many shares of Arcutis Biotherapeutics, Inc. - Common stock are outstanding?
Arcutis Biotherapeutics, Inc. - Common stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.